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Edited by Sandro SonninoAbstract We screened sera from patients with various neuro-
logical disorders for the presence of anti-neutral glyco-
sphingolipids antibodies and only found them in sera from
relapsing polychondritis with limbic encephalitis patients.
Neutral glycosphingolipids are resident in membrane lipid
rafts where high aﬃnity nerve growth factor (NGF) receptor,
Trk is co-localized. Therefore, we examined whether these anti-
bodies inﬂuence the action of NGF in NGF-responsive cells. The
results strongly suggest that these antibodies enhance NGF-in-
duced Trk autophosphorylation and neurite outgrowth as well
as neuroﬁlament M expression. These data strongly indicate that
these anti-neutral glycosphingolipids antibodies have an func-
tional impact on NGF-Trk-mediated intracellular signal trans-
duction pathway.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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growth factor1. Introduction
There is an accumulating evidence that suggests the patho-
gnomonic linkage between anti-gangliosides antibodies and
acute motor axonal neuropathy and the cranial, bulbar and
sensory variants of Guillain-Barre´ syndrome [1]. Inspite of so
many publications at present, their real roles for the develop-
ment of the neuropathies still remain to be elucidated. Gan-
gliosides are acidic glycosphingolipids comprising a ceramide
moiety embedded in the lipid bilayer and sialylated oligosac-
charide core that is extracellularly displayed and capable of
acting as an autoantibody target [2]. On the contrary, there
is a few investigation on anti-neutral glycosphingolipids
antibodies in neurological disorders. Major neutral glyco-
sphingolipids include glucosylceramide (GlcCer), lactosylcera-
mide (LacCer), globotriaosylceramide, globoside or
galactosylceramide (GalCer). It has been only reported that*Corresponding author. Fax: +81 562 93 1856.
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doi:10.1016/j.febslet.2006.08.013anti-GalCer antibody is present in patients with GBS after
Mycoplasma pneumoniae infection [3]. GlcCer is one of the car-
dinal neutral glycosphingolipids. It is located in the plasma
membrane primarily in lipid rafts, a special membrane struc-
ture that also contains many signaling moieties such as recep-
tor-type tyrosine kinases, cholesterol, sphingomyelin, and
glycosphingolipids [4]. GlcCer is synthesized from ceramide
through the enzymatic action of GlcCer synthase and consti-
tutes the ﬁrst step in the synthesis of all types of gangliosides.
GlcCer is involved in the regulation of many biological events
such as neuronal apoptosis and drug resistance to anti-cancer
drugs [5,6]. Additionally, GlcCer induces neuronal growth and
epidermal diﬀerentiation [7,8].
In this study, we screened sera from patients with various
kinds of neurological disorders for the presence of an antibody
against neutral glycosphingolipids and found novel anti-neu-
tral glycosphingolipids antibodies against GlcCer and GalCer
but not LacCer only in sera from the patients with relapsing
polychondritis (RP) complicated by limbic encephalitis (LE)-
like symptoms. These antibodies were not found in sera from
normal controls or patients with other neurological disorders
to include uncomplicated RP. Then, we tried to characterize
these anti-neutral glycosphingolipid antibodies using rat pheo-
chromocytoma cell-line, PC12 cells. Unexpectedly, these novel
antibodies enhanced the action of nerve growth factor (NGF)
in cultured PC12 cells. This enhancement was mediated
through NGF-induced Trk, a high aﬃnity nerve growth factor
receptor exhibiting tyrosine kinase activity, autophosphoryla-
tion response. The data clearly suggests that anti-neutral
glycosphingolipids antibodies have an impact on the Trk-
mediated intracellular signaling pathway.2. Materials and methods
2.1. Human sera
After obtaining informed consent, sera were taken from various neu-
rological patients (13 patients with viral encephalitis, 5 patients with
paraneoplastic neurological syndrome, 5 patients with Guillain-Barre´
syndrome, 4 patients with Sjo¨gren syndrome, and 5 patients with Par-
kinson’s disease, 3 patients with RP complicated by LE and 2 patients
with RP without LE) and 13 normal controls. The samples were stored
at 20 C until use. All of the RP + LE patients exhibited psychiatric
symptoms such as memory disturbance and delusions. The develop-
ment of these symptoms coincided with the onset of canonical symp-
toms of RP such as ear swelling and erythema.blished by Elsevier B.V. All rights reserved.
Fig. 2. Immunoreactivity against chemically synthesized pure GlcCer.
Chemically synthesized pure GlcCer were electrothermally blotted
onto a polyvinylidene diﬂuoride membrane. The membrane was
probed with sera from patients with RP + LE (1) and from disease
controls (2). Red asterisks indicate the positive bands corresponding to
GlcCer. (For interpretation of the references to color in this ﬁgure
legend, the reader is referred to the web version of this article.)
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To evaluate the patients’ sera for the presence of anti-neutral glyco-
sphingolipids antibodies, puriﬁed GlcCer (a generous gift from Dr.
Hirabayashi Y. Brain science Institute, RIKEN, Wako, Japan), Gal-
Cer (a generous gift from Dr. Furukawa K., Nagoya University School
of Medicine, Nagoya, Japan), and LacCer (BioMol, USA) were pro-
cessed by thin-layer chromatography (using a solvent of chloroform,
methanol, and distilled water in a 55:20:3 vol/vol/vol ratio) and blotted
onto a polyvinylidene diﬂuoride membrane by an electrothermal blot-
ter (ATTO Co. Ltd., Tokyo, Japan) as described previously [9]. This
polyvinylidene diﬂuoride (PVDF) membrane was probed with human
sera (500· dilution) in blocking buﬀer (2% non-fat milk in the wash
buﬀer phosphate-buﬀered saline (PBS) containing 1% Triton X-100).
Following application of the second antibody, a positive band was de-
tected with an enhanced chemiluminescence reagent (Perkin–Elmer
Inc., Boston, MA). In some case, we also examined the presence of
anti-GlcCer antibody using chemically synthesized pure GlcCer (from
Dr. Y. Hirabayashi).
2.3. Cell culture and treatment
Rat pheochromocytoma-derived PC12 cells and stable transfectants
of human trk-complimentary DNA (PCtrk cells) were cultured as de-
scribed [10]. The cells were cultured as monolayers in DMEM contain-
ing 7.5% FBS, 100 U/ml penicillin and 100 lg/ml streptomycin [11].
Cells were incubated at 37 C in a humidiﬁed 5% CO2 atmosphere.
For morphological observation, cells were cultured in 24-well culture
plates and examined using a phase contrast microscope [12]. Following
photography, the cells were lysed in sodium dodecyl sulfate (SDS)-
sample buﬀer and evaluated by immunoblot analysis using an anti-
neuroﬁlament M antibody for neuronal diﬀerentiation as described
previously [11].
2.4. Immunoprecipitation and immunoblot analysis
Because both neutral glycosphingolipids and Trk are located in the
membrane lipid raft, a membrane structure that is also the site of trans-
membrane signaling, we examined the eﬀect of anti-neutral glyco-
sphingolipids antibodies on the high aﬃnity NGF receptor, Trk.
PCtrk cells were preincubated with sera (500· dilution) for 30 min
and then stimulated with 50 ng/ml nerve growth factor (NGF) for
5 min. To evaluate receptor activity, Trk was immunoprecipitated with
an anti-Trk antibody (a-Trk; Santa Cruz Biotechnology Inc., Santa
Cruz, CA) and subjected to immunoblot analysis using either an
anti-phosphotyrosine antibody (a-PY, 4G10, Upstate Biotechnol.
Inc., Lake Placid, NY) or a-Trk antibody as described [10–12]. In some
case, antibody-positive sera were precleared with protein-L agarose to
remove all immunoglobulins for 4 h in the cold room with agitation.Fig. 1. Immunoblot analysis for neutral glycosphingolipids. Neutral
glycosphingolipids (GlcCer and LacCer (lanes a(1), b(1) and c(1)),
GalCer (lanes a(2), b(2) and c(2)) were electrothermally blotted onto a
polyvinylidene diﬂuoride membrane. The membrane was probed with
sera from the patients with RP + LE obtained before (a) and after (c)
steroid hormone therapy and with sera from patients with only RP (b).
The position of each neutral glycosphingolipids was determined on a
high-performance thin-layer chromatography plate developed simul-
taneously without electrothermal blotting. Red asterisks indicate the
positive bands corresponding to GlcCer () and to GalCer (). (For
interpretation of the references to color in this ﬁgure legend, the reader
is referred to the web version of this article.)
Fig. 3. Eﬀect of sera on Trk-tyrosine kinase activity in response to
NGF. PCtrk cells were cultured on 15 cm in diameter culture dishes and
were pretreated with serum-free medium for 1 h. (a) Then, cells were
treated with sera (·200 diluted in ﬁnal) (lane 3, patient with RP + LE;
lane 4, another patient with RP + LE; same patient with RP + LE
obtained after steroid hormone treatment) for 30 min and stimulated
with 50 ng/ml NGF (lanes 2–5) or without (lane 1) for 5 min. (b) Cells
were treated with sera (·200 diluted in ﬁnal) (lanes 3, 4, patients with
RP only; lane 5, disease control (Parkinson’s disease); lane 6, a normal
control) for 30 min and stimulated with 50 ng/ml NGF (lanes 2–6) or
without (lane 1) for 5 min. After stimulation, cells were collected with
chilled PBS and subjected to the immunoprecipitation as described in
‘‘Section 2’’. These were performed at least three times with identical
results. Arrows indicate position of the Trk protein.These precleared sera were subjected to Trk-immunoprecipitation.
Detection of positive bands was performed using Western blot Chemi-
luminescence Reagent Plus (Perkin–Elmer Inc.) [8,10].
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The concentration of NGF concentrations in sera were measured by
commercial ELISA kit (Promega, USA) according to the manufac-
turer’s instructions. To neutralize the eﬀects of serum immunoglobu-
lins, protein-L agarose was added and incubated with agitation for
2 h in the cold. Following agitation, the sera were centrifuged at
12000 rpm for 2 min and resultant supernatants subject to evaluation.
Each evaluation was performed in a triplicate.Fig. 5. NGF concentrations. Serum NGF concentration was mea-
sured by ELISA. RP + LE sera before the treatment (column 1, n = 3),
with RP + LE after the treatment (column 2, n = 3), disease controls
including RP without LE (column 3, n = 34), and normal controls
(column 4, n = 13). The columns represent the means ± S.D.3. Results
3.1. Detection of anti-neutral glycosphingolipid antibodies
A total of 50 serum samples were screened. Positive bands
representing antibodies against GlcCer and GalCer were found
in sera obtained from patients with RP + LE (Fig. 1a). These
antibodies were not found in any of the patients with other
neurological disorders to include RP in the absence of LE
(Fig. 1b) or in the normal controls (data not shown). Intrigu-
ingly, after a course of steroids (pulse therapy followed by oral
prednisolone), all of the RP + LE patients who were positive
for anti-neutral glycosphingolipid antibodies had a remarkable
improvement in their clinical symptoms that was accompanied
by a disappearance of these autoantibodies (Fig. 1c). Further-
more, these anti-neutral glycosphingolipids antibodies in pa-
tients’ sera actually recognize chemically synthesized pure
GlcCer (Fig. 2).
3.2. Eﬀect on NGF-induced Trk autophosphorylation
To evaluate the eﬀects of the antibodies-positive sera on
NGF-induced Trk autophosphorylation, PCtrk cells were pre-
treated with sera for 30 min followed by 5 min of NGF stimu-
lation and immunoprecipitated the Trk protein. Sera positiveFig. 4. Morphological eﬀects of RP + LE sera on NGF-induced neurite out
presence of 50 ng/ml of NGF (2–4, 7, 8) or absence of NGF (1, 5, 6) for 12 h
before any treatment (3, 5) or after treatment (4, 6) and from RP patient (7)
neuroﬁlament M in the total cell lysates prepared from those used for morph
antibody. Note that RP + LE patient’s serum before treatment strongly aug
after treatment nor disease and normal controls. These experiments were perfo
neuroﬁlament M.for an anti-neutral glycosphingolipid antibodies augmented
NGF-induced Trk autophosphorylation (Fig. 3a). Sera nega-
tive for anti-neutral glycosphingolipid antibodies had no eﬀect
on NGF-induced Trk autophosphorylation (Fig. 3b). Intrigu-
ingly, sera from RP + LE patient obtained after treatment with
steroid hormone and precleared with protein-L agarose did not
reveal no augmentation of NGF-induced Trk autophosphory-
lation (compare Fig. 3a(4 and 5) and data not shown).growth in PCtrk cells. PCtrk cells were cultured on 24-well dish in the
. Before adding NGF, cells were pre-treated with patient’s serum taken
and normal control (8) for 30 min. We also examined the expression of
ological studies by the immunoblot analysis with anti-neuroﬁlament M
mented NGF-induced neurite outgrowth in PCtrk cells but not taken
rmed three times with identical results. Arrows indicate the position of
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To reinforce the previous ﬁndings, we also examined the
eﬀect of sera on NGF-induced morphological diﬀerentiation.
In PCtrk cells, NGF-induced neurite outgrowth was enhanced
by RP + LE patient sera when compared to the eﬀect of NGF
alone (Fig. 4). This enhancement was not observed with anti-
neutral glycosphingolipid antibodies-negative sera from con-
trols and other neurologic disorders to include LE negative
RP. Additionally, the eﬀect of sera on neuroﬁlament M expres-
sion was also examined by immunoblot analysis. As was the
case with neurite outgrowth, RP + LE sera taken before the
treatment with steroid hormone enhanced neuroﬁlament
M expression but not taken after treatment nor disease and
normal controls when compared to the eﬀect of NGF alone
(Fig. 4). Moreover, precleared sera from patients with
RP + LE with protein-L agarose also did not induce such
enhancement (data not shown).3.4. Measurement of serum NGF concentration
To test the possibility that serum NGF concentrations are
increased in anti-neutral glycosphingolipids antibody-positive
sera, NGF concentrations were measured. This is no diﬀerence
in NGF concentrations between antibody positive and anti-
body negative sera (Fig. 5).4. Discussion
The present study clearly demonstrates the presence of novel
anti-neutral glycosphingolipid antibodies in the sera of pa-
tients with RP + LE. These autoantibodies were not found in
normal controls or in patients with a variety of other neurolog-
ical disorders. It is particularly intriguing that all of LE-nega-
tive RP patients do not exhibit these antibodies. In all RP +
LE patients, following a therapeutic course of steroids these
autoantibodies were no longer present and this absence coin-
cided with clinical recovery and resolution of MRI ﬁndings.
There is only few case reports disclosing the complication of
LE in RP patients [13]. Therefore, it is quite diﬃcult to collect
sera from such patients at present, although all of RP + LE
patients in the present study exhibit anti-neutral glyco-
sphingolipids antibodies. The speciﬁcity of these antibodies
in relation to other neurological disorders should be examined
on further patients.
What is the molecular mechanisms for the development of
the present autoantibodies to neutral glycosphingolipids?
Interestingly, auricular cartilage contains large amounts of
neutral glycosphingolipids [14]. Patients with RP demonstrate
marked auricular inﬂammation and induration, particularly so
in the patients in this study. Therefore, we speculate that the
abundance of these neutral glycosphingolipids in areas subject
to destruction by the inﬂammatory process would make them
preferred targets for an autoimmune response, although we
have to examine further this hypothesis. In this regard, it is
quite interesting that a recent report by Yamaguchi et al. dem-
onstrates that autoantibodies to GM2 ganglioside are pro-
duced in the rat model of GM2 ganglioside-storage disease
[15], GM2 gangliosidosis, although GM2 ganglioside is a nor-
mal constituent of membrane lipids.
These new anti-neutral antibodies have an impact on Trk-
mediated intracellular signaling pathway as shown in thisstudy. NGF is a cardinal neuroprotective, neurotrophic factor
that promotes both neuronal survival and diﬀerentiation [16].
The initial step in the intracellular signal transduction of
NGF is the activation of Trk-associated tyrosine kinase activ-
ity through the autophosphorylation of tyrosine residues [17].
Therefore, we speculated that these antibodies have a negative
eﬀects on Trk-mediated signaling pathway, because it seems
these anti-neutral glycosphingolipids antibodies as a patho-
gnomonic factor for the development of LE in RP. Unexpect-
edly, these antibodies enhances NGF-induced Trk
autophosphorylation in PCtrk cells. This result suggests that
these antibodies might promote Trk receptor clustering, be-
cause both are located in the same membrane structure, lipid
rafts on the membrane platform. We have already observed
similar phenomena where a speciﬁc ligand for GM1 ganglio-
side that is membrane raft-resident glycosphingolipids en-
hances NGF-induced Trk autophosphorylation [18]. These
enhancing eﬀects of the antibodies-positive sera were also ob-
served in the experiments of NGF-induced neurite outgrowth
and neuroﬁlament M expression. The sera that is precleared
with protein-L agarose to remove serum immunoglobulins do
not exhibit such enhancing eﬀects anymore, suggesting that
immunoglobulins in antibodies-positive sera are the responsi-
ble molecules for such enhancement. This interpretation was
supported by the data on NGF concentration in sera. As
described earlier, NGF concentrations in antibodies-positive
sera were not diﬀerent in those of antibodies-negative sera.
Currently, there are no reliable antibodies directed against
GlcCer and GalCer. These autoantibodies may provide a solu-
tion to this problem and provide new tools for basic research
on neutral glycosphingolipids in neurons.
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